Jundishapur Journal of Microbiology

Published by: Kowsar

The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran

Pegah Karimi Elizee 1 , 2 , 3 , Seyed Moayed Alavian 1 , 2 , 3 , * , Seyyed Mohammad Miri 1 , 2 , 3 , Bita Behnava 1 , 2 , 3 , Seyedeh Hoda Alavian 4 , Maryam Keshvari 5 , Mohammad Gholami Fesharaki 6 , Shima Salimi 2 , 3 , Leila Mehrnoush 2 , 3 and Mostafa Shafiei 2 , 3
Authors Information
1 Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver diseases, Tehran, IR Iran
2 Middle East Liver Disease Center, Tehran, IR Iran
3 Tehran Hepatitis Center, Tehran, IR Iran
4 Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
5 Iranian Blood Transfusion Organization research Center, Tehran, IR Iran
6 Biostatistics Department, Tarbiat Modarres University, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2013, 6 (7); e9091
  • Published Online: September 1, 2013
  • Article Type: Research Article
  • Received: November 11, 2012
  • Revised: February 19, 2013
  • Accepted: April 11, 2013
  • DOI: 10.5812/jjm.9091

To Cite: Karimi Elizee P, Alavian S M, Miri S M, Behnava B, Alavian S H, et al. The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran, Jundishapur J Microbiol. 2013 ; 6(7):e9091. doi: 10.5812/jjm.9091.

Copyright © 2013, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Wasley A, Feinstone SM, Bell BP. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 2010; : 2367-89
  • 2. Anderson DA. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 2010; : 2411-23
  • 3. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol. 2001; 33(1): 20-6[PubMed]
  • 4. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009; 49(10): 2195-9[DOI][PubMed]
  • 5. Keshvari M, Alavian SM, Behnava B, Miri SM, Elizee PK, Tabatabaei SV, et al. Distribution of hepatitis C virus genotypes in iranian patients with congenital bleeding disorders. Iran Red Crescent Med J. 2010; 12(6): 608-14
  • 6. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8: 84-90
  • 7. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338(5): 286-90[DOI][PubMed]
  • 8. Cho HC, Paik SW, Kim YJ, Choi MS, Lee JH, Koh KC, et al. Seroprevalence of anti-HAV among patients with chronic viral liver disease. World J Gastroenterol. 2011; 17(2): 236-41[DOI][PubMed]
  • 9. Atiq M, Shire NJ, Barrett A, Rouster SD, Sherman KE, Shata MT. Hepatitis E virus antibodies in patients with chronic liver disease. Emerg Infect Dis. 2009; 15(3): 479-81[DOI][PubMed]
  • 10. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit. 2003; 9(1)-22[PubMed]
  • 11. Siagris D, Kouraklis-Symeonidis A, Konstantinidou I, Christofidou M, Starakis I, Lekkou A, et al. Prevalence of anti-HAV antibodies in multitransfused patients with beta-thalassemia. World J Gastroenterol. 2008; 14(10): 1559-63[PubMed]
  • 12. Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. East Mediterr Health J. 2011; 17(10): 754-8[PubMed]
  • 13. Vilibic-Cavlek T, Kucinar J, Ljubin-Sternak S, Kolaric B. Seroepidemiology of hepatitis a in the croatian population. Hepat Mon. 2011; 11(12): 997-9[DOI][PubMed]
  • 14. Luksamijarulkul P, Sujirarat D, Charupoonphol P. Risk Behaviors, Occupational Risk and Seroprevalence of Hepatitis B and A Infections among Public Cleansing Workers of Bangkok Metropolis . Hepat Mon. 2008; 8(1): 35-40
  • 15. Ghorbani GA. Is evaluation of hepatitis a immunity required or not? Hepat Mon. 2011; 11(12): 955-7[DOI][PubMed]
  • 16. Scaraggi FA, Perricci A, Petronelli M, Lomuscio S, De Mitrio V, Schiraldi O. Prevalence of serum IgG antibodies to hepatitis A virus in Italian haemophiliacs. Lancet. 1992; 339(8807): 1486-7[PubMed]
  • 17. Mosley JW. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States? Vox Sang. 1994; 67 Suppl 4: 12-5[PubMed]
  • 18. Kreuz W, Klarmann D, Auerswald G, Auberger K, Gurtler L, Rabenau H, et al. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease. Lancet. 1993; 341(8842): 446[PubMed]
  • 19. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994; 271(17): 1328-34[PubMed]
  • 20. Mohebbi SR, Rostami Nejad M, Tahaei SM, Pourhoseingholi MA, Habibi M, Azimzadeh P, et al. Seroepidemiology of hepatitis A and E virus infections in Tehran, Iran: a population based study. Trans R Soc Trop Med Hyg. 2012; 106(9): 528-31[DOI][PubMed]
  • 21. Saffar MJ, Abedian O, Ajami A, Abedian F, Mirabi AM, Khalilian AR, et al. Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review. Hepat Mon. 2012; 12(5): 326-32[DOI][PubMed]
  • 22. Ghadir MR, Jafari E, Rezvan H, Amini-Kafiabad S, Vaeze-Javadi M, Pourshams A. Hepatitis A and E in the east of Golestan province. J Med Council I.R.I. 2007; 25(1): 34-8
  • 23. Taghavi SA, Hosseini Asl MK, Talebzadeh M, Eshraghian A. Seroprevalence study of hepatitis A virus in Fars province, southern Iran. Hepat Mon. 2011; 11(4): 285-8[PubMed]
  • 24. Shoaei P, Zeidabadinejad L, Hassannejad R, Ataei B, Yaran M, Kassaian N, et al. Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province. Int J Prev Med. 2012; 3-6[PubMed]
  • 25. Johnson Z, Thornton L, Tobin A, Lawlor E, Power J, Hillary I, et al. An outbreak of hepatitis A among Irish haemophiliacs. Int J Epidemiol. 1995; 24(4): 821-8[PubMed]
  • 26. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998; 38(6): 573-9[PubMed]
  • 27. Brackmann HH, Oldenburg J, Eis-Hubinger AM, Gerritzen A, Hammerstein U, Hanfland P. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang. 1994; 67 Suppl 1: 3-7[PubMed]
  • 28. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med. 1994; 120(1): 1-7[PubMed]
  • 29. Kedda MA, Kew MC, Cohn RJ, Field SP, Schwyzer R, Song E, et al. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology. 1995; 22(5): 1363-7[PubMed]
  • 30. Normann A, Graff J, Gerritzen A, Brackmann HH, Flehmig B. Detection of hepatitis A virus RNA in commercially available factor VIII preparation. Lancet. 1992; 340(8829): 1232-3[PubMed]
  • 31. Steele M, Cochrane A, Wakefield C, Stain AM, Ling S, Blanchette V, et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia. 2009; 15(2): 437-47[DOI][PubMed]
  • 32. Chambost H, Doncarli A, Bertrand MA, Briquel ME, Gay V, Pincemaille O, et al. Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort. Haemophilia. 2007; 13(6): 712-21[DOI][PubMed]
  • 33. Hayashi K, Fukuda Y, Nakano I, Katano Y, Nagano K, Yokozaki S, et al. Infection of hepatitis A virus in Japanese haemophiliacs. J Infect. 2001; 42(1): 57-60[DOI][PubMed]
  • 34. Toyoda H, Honda T, Hayashi K, Katano Y, Goto H, Kumada T, et al. Prevalence of hepatitis E virus IgG antibody in Japanese patients with hemophilia. Intervirology. 2008; 51(1): 21-5[DOI][PubMed]
  • 35. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 2009; 24(9): 1484-93[DOI][PubMed]
  • 36. Ariyegan M, Amini S. Hepatitis E epidemic in Iran. J Med Council I.R. Irn . 1998; 15: 139-43
  • 37. Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmodi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. East Mediterr Health J. 2009; 15(1): 136-42[PubMed]
  • 38. Ataei B, Nokhodian Z, Javadi AA, Kassaian N, Shoaei P, Farajzadegan Z, et al. Hepatitis E virus in Isfahan Province: a population-based study. Int J Infect Dis. 2009; 13(1): 67-71[DOI][PubMed]
  • 39. Taremi M, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. East Mediterr Health J. 2007; 13(1): 98-102[PubMed]
  • 40. Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SA. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran. Int J Infect Dis. 2008; 12(4): 387-90[DOI][PubMed]
  • 41. Shamsizadeh A, Nikfar R, Makvandi M, Shamsizadeh N. Seroprevalence of Hepatitis E Virus Infection in Children in the Southwest of Iran. Hepat Mon. 2009; 9(4): 261-4
  • 42. Taremi M, Mohammad Alizadeh AH, Ardalan A, Ansari S, Zali MR. Seroprevalence of hepatitis E in Nahavand, Islamic Republic of Iran: a population-based study. East Mediterr Health J. 2008; 14(1): 157-62[PubMed]
  • 43. Rostamzadeh Khameneh Z, Sepehrvand N, Masudi S. Seroprevalence of Hepatitis E among Iranian Renal Transplant Recipients. Hepat Mon. 2011; 11(8): 646-51[PubMed]
  • 44. al-Fawaz I, al-Rasheed S, al-Mugeiren M, al-Salloum A, al-Sohaibani M, Ramia S. Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassemia major: possible transmission by blood transfusion. J Viral Hepat. 1996; 3(4): 203-5[PubMed]
  • 45. Mannucci PM, Gringeri A, Santagostino E, Romano L, Zanetti A. Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates. Lancet. 1994; 343(8897): 597-8[PubMed]
  • 46. Klarmann D, Kreuz W, Kornhuber B. Low prevalence of hepatitis E virus antibodies in hepatitis C virus-positive patients with coagulation disorders. Transfusion. 1995; 35(11): 969-70[PubMed]
  • 47. Zaaijer HL, Mauser-Bunschoten EP, ten Veen JH, Kapprell HP, Kok M, van den Berg HM, et al. Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients. J Med Virol. 1995; 46(3): 244-6[PubMed]
  • 48. Barzilai A, Schulman S, Karetnyi YV, Favorov MO, Levin E, Mendelson E, et al. Hepatitis E virus infection in hemophiliacs. J Med Virol. 1995; 46(2): 153-6[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments